We are successfully executing on our strategy with continued advancements in important CDMO projects, ramping up new launches and strengthened leadership in antiretroviral in driving strong quarter and cumulative performance. These results confirm our Full year outlook of strong revenue growth and improving margin momentum. Investments to continuously enhance service capability of Peptide technology platforms and ADC/Gene therapy is on track to meet current and future goals. We are confident that we are investing into interesting pipeline opportunities and these projects will continue to transform our Business portfolio and drive future growth with continued progress on ESG commitments.

We delivered another quarter of strong operational and financial performance, based on strong Generic business and continued demand upside in CDMO small molecule offerings. We have achieved revenues of ₹ 1,778 Cr, representing 26% growth and EBITDA of ₹ 485 Cr, representing 70% growth. The EBITDA margins stood at 27.3%, supported by continuing operating leverage. Overall, we reported strong 9M performance. We achieved ₹ 5,001 Cr in revenues, representing 30% growth and EBITDA of ₹ 1,303 Cr, representing 104% growth, resulting in 26.1% EBITDA margins marking over 9% pts improvement over last year. Gross margins improved by over 4.3% pts to 60.1% due to favorable CDMO mix. Net Debt leverage decreased further to 1.2x EBITDA despite continuing CAPEX investments. We will continue investing behind high value business opportunities to drive near and long-term growth.